This course has expired. View available courses.
Medication Management, Oncology
Ribociclib (Kisqali®): a guide for oncologists to optimise practice – Certificate of Completion
Approximately 30% of individuals diagnosed with HR+ breast cancer will eventually experience relapse with metastatic disease. Endocrine therapy targeting the estrogen receptor has historically been a fundamental component of treatment in the metastatic setting. First-line treatment previously recommended for post-menopausal women with HR+/HER2- metastatic breast cancer included either aromatase inhibitors or selective estrogen receptor degraders. Resistance to endocrine therapy in women with HR+ metastatic disease frequently occurs, however, with a number of different mechanisms being implicated. This has prompted the need for newer treatment options.
DURATION
30 mins
PROFESSION
Specialist
# OF CREDITS
0.5
ACCREDITATION
Unaccredited
EXPIRY DATE
2021-05-28
Hormone-receptor positive (HR+) breast cancer accounts for between 60-80% of all breast cancer cases, with the HR+/HER2- subtype having been identified as the most predominant in Western countries.
Approximately 30% of individuals diagnosed with HR+ breast cancer will eventually experience relapse with metastatic disease. Endocrine therapy targeting the estrogen receptor has historically been a fundamental component of treatment in the metastatic setting. First-line treatment previously recommended for post-menopausal women with HR+/HER2- metastatic breast cancer included either aromatase inhibitors or selective estrogen receptor degraders. Resistance to endocrine therapy in women with HR+ metastatic disease frequently occurs, however, with a number of different mechanisms being implicated. This has prompted the need for newer treatment options.
Faculty
Professor Frances Boyle
MBBS, PhD, FRACP, GAICD
Professor of Medical Oncology, University of Sydney
Medical Oncologist, Mater Hospital, North Sydney, NSW
Richard de Boer
MBBS, FRACP
Consultant Medical Oncologist,
Peter MacCallum Cancer Centre, Melbourne, VIC